Biology subjects

Pergola, G.

Publications and source records attributed to Pergola, G..

13 recordsLinked to original sources

bioRxiv2026

Liquidity of gene co-expression trajectories across the lifespan highlights delayed maturation and the perinatal GABA switch in schizophrenia risk

Schizophrenia genetic and environmental risk factors play out largely in early life, biasing development toward a pathogenic trajectory that becomes clinically apparent in early adulthood, when the disorder typically onsets. Here, we convert snapshots of gene expression in postmortem brain at a moment in time into a dynamic lifetime series employing the "liquidity" metric, a novel tool to track the evolution of networks across time from a multi-systemic perspective. The landscape of normal prefrontal cortical development becomes increasingly "liquid" during the first two decades of post-natal life, with sharp discontinuities in known critical periods such as birth and adolescence. Neurotypical individuals free of apparent neuropathology with relatively elevated polygenic risk scores for schizophrenia exhibit a generalized delay in the dynamics of liquidity across these trajectories compared to below-average-risk individuals. Impacted biological processes strongly converge on delayed GABA-A receptor functional maturation, involved in establishing Excitatory/Inhibitory balance in brain during early development. Similar to patients with schizophrenia, neurotypical high-risk individuals show an increased expression ratio between the genes SLC12A2 (protein NKCC1) and SLC12A5 (protein KCC2) relative to low-risk, involved in the control of the equilibrium potential of chloride ions that regulates GABA-A function. These results provide evidence that genetic risk for schizophrenia is associated with a delayed maturational profile and delayed maturation of GABAergic signaling without detectable neuropathology and well before the age of clinical onset. Interestingly, the same effect is not observed in the hippocampus and is not observed with genetic risk for other neuropsychiatric and immune conditions. The dynamics of maturation of GABA-A signaling in the dorsolateral prefrontal cortex emerge as an early contributor to translating genetic risk into an altered developmental trajectory associated with schizophrenia.

genomics↗

bioRxiv2026

Genetic Risk and Resilience for Schizophrenia Stratified by Perinatal Gene Expression Predict Adult Cognitive Performance

Genetic risk for schizophrenia (SCZ) has been linked to cognitive performance before the onset age. We examined how SCZ-related polygenic risk and resilience variants, and their co-expression patterns in the human brain, were associated with cognitive abilities across development in 16,520 non-psychiatric European and African ancestry children and adults. SCZ risk showed significant negative associations with spatial, verbal, and working memory across ancestries (all t<-2, pFDR<0.05). In Europeans, risk and resilience variants had opposing effects on attention, working and spatial memory ({Delta}t>4, pFDR<0.05). Polygenic scores filtered through perinatal co-expression networks showed stronger links with cognition than adult ({Delta}AIC>5.75, p=0.02) or juvenile ({Delta}AIC>5.8, p=0.03) networks. Cross-ancestry correlations (R=0.52, p<0.01) highlight replicability. These findings support the neurodevelopmental basis of SCZ, suggesting that risk and resilience variants influence cognition from early life, independent of symptoms and elucidate biological pathways through which SCZ risk may influence early cognitive development.

genomics↗

bioRxiv2024

Transcriptomics and proteomics of projection neurons in a circuit linking hippocampus with dorsolateral prefrontal cortex in human brain

Transcriptome and proteome sequencing of brain tissue homogenate has helped unravel processes underlying schizophrenia (SCZ). However, most studies have lacked granularity at the cell type level and have focused on individual brain regions, rather than examining expression dynamics across multiple regions or illness-relevant circuitries. We used laser capture microdissection to collect excitatory neuron-enriched samples from hippocampal subregions CA1 and presubiculum (SUB), and from dorsolateral prefrontal cortex (DLPFC), a circuit prominently implicated in schizophrenia. Using RNA sequencing and quantitative proteomics, we show significantly superior discrimination of brain regional identity in the transcriptomic (>90% accuracy) and proteomic data (>97% accuracy) compared with gene-level expression data (<70% in bulk). Patients with SCZ show hippocampal-specific differential protein phosphorylation. SCZ risk co-expression gene-sets that replicate across transcript and protein networks are enriched for transmembrane transporters in the DLPFC and CA1 and postsynaptic processes in the SUB. We demonstrate a strong directional connectivity effect of SCZ risk in that excitatory synaptic genes in CA1 unidirectionally predict gene expression in SUB. Finally, parallel CA1 snRNA-seq results suggest that in SCZ excitatory efferents in CA1 are affected by interactions with glia and by downregulation of inhibitory neuropeptide inputs. Our study proposes molecular mechanisms by which hippocampal communication, previously associated with SCZ at the macroscopic level, may be altered at the inter-field and interregional circuit level.

neuroscience↗

bioRxiv2023

Dopamine and schizophrenia from bench to bedside: Discovery of a striatal co-expression risk gene set that predicts in vivo measures of striatal function.

Schizophrenia (SCZ) is characterized by a polygenic risk architecture implicating diverse molecular pathways important for synaptic function. However, how polygenic risk funnels through these pathways to translate into syndromic illness is unanswered. To evaluate biologically meaningful pathways of risk, we used tensor decomposition to characterize gene co-expression in post-mortem brain (of neurotypicals: N=154; patients with SCZ: N=84; and GTEX samples N=120) from caudate nucleus (CN), hippocampus (HP), and dorsolateral prefrontal cortex (DLPFC). We identified a CN-predominant gene set showing dopaminergic selectivity that was enriched for genes associated with clinical state and for genes associated with SCZ risk. Parsing polygenic risk score for SCZ based on this specific gene set (parsed-PRS), we found that greater pathway-specific SCZ risk predicted greater in vivo striatal dopamine synthesis capacity measured by [18F]-FDOPA PET in three independent cohorts of neurotypicals and patients (total N=235) and greater fMRI striatal activation during reward anticipation in two additional independent neurotypical cohorts (total N=141). These results reveal a bench to bedside translation of dopamine-linked genetic risk variation in driving in vivo striatal neurochemical and hemodynamic phenotypes that have long been implicated in the pathophysiology of SCZ.

neuroscience↗

bioRxiv2021

A Biologically Interpretable Graph Convolutional Network to Link Genetic Risk Pathways and Neuroimaging Phenotypes of Disease

AO_SCPLOWBSTRACTC_SCPLOWWe propose a novel end-to-end framework for whole-brain and whole-genome imaging-genetics. Our genetics network uses hierarchical graph convolution and pooling operations to embed subject-level data onto a low-dimensional latent space. The hierarchical network implicitly tracks the convergence of genetic risk across well-established biological pathways, while an attention mechanism automatically identifies the salient edges of this network at the subject level. In parallel, our imaging network projects multimodal data onto a set of latent embeddings. For interpretability, we implement a Bayesian feature selection strategy to extract the discriminative imaging biomarkers; these feature weights are optimized alongside the other model parameters. We couple the imaging and genetic embeddings with a predictor network, to ensure that the learned representations are linked to phenotype. We evaluate our framework on a schizophrenia dataset that includes two functional MRI paradigms and gene scores derived from Single Nucleotide Polymorphism data. Using repeated 10-fold cross-validation, we show that our imaging-genetics fusion achieves the better classification performance than state-of-the-art baselines. In an exploratory analysis, we further show that the biomarkers identified by our model are reproducible and closely associated with deficits in schizophrenia.

bioinformatics↗

bioRxiv2021

Investigating trait variability of gene co-expression network architecture in brain by manipulating genomic signatures of schizophrenia risk

While the role of genomic risk for schizophrenia on brain gene co-expression networks has been described, the patterns of its manifestations are varied and complex. To acquire a deeper understanding of this issue, we implemented a novel approach to network construction by manipulating the RNA-Seq expression input to "integrate" or "remove" the "modulatory" effects of genomic risk for schizophrenia. We created co-expression networks in DLPFC from the adjusted expression input and compared them in terms of gene overlap and connectivity. We used linear regression models to remove variance explained by RNA quality, cell type proportion, age, sex and genetic ancestry. We also created co-expression networks based on the genomic profile of a normative trait, height, as a "negative control"; we also applied the same analytical approach in two independent samples: LIBD Human Brain Repository (HBR) (N=78 brains, European ancestry) and Common Mind Consortium (CMC) (N=116 brains, European ancestry). In addition to direct comparisons, we explored the biological plausibility of the differential gene clusters between co-expression networks by testing them for enrichment in relevant gene ontologies and gene sets of interest (PGC2-CLOZUK GWAS significant loci genes, height GWAS significant loci genes, genes in synaptic ontologies-SynGO and genes of the "druggable genome"). We identify several key aspects of the role of genomic risk for schizophrenia in brain co-expression networks: 1) Variability of co-expression modules with "integration" or "removal" of genomic profiles of complex traits (normal or pathological); 2) Biological plausibility of gene sets represented in the differential co-expression contrasts and potential relevance for illness etiopathogenesis; 3) Non-preferential mapping of schizophrenia GWAS loci genes to network areas apparently influenced by the genomic risk score. Overall, our study supports the notion that genomic risk for schizophrenia has an extensive and non-linear effect on brain gene co-expression networks that possibly manifests as a molecular background for gene-gene, gene-environment interactions that affect various biological pathways.

genomics↗

bioRxiv2020

A miR-137-related biological pathway of risk for Schizophrenia is associated with human brain emotion processing

Genome-Wide-Association studies have involved miR-137 in schizophrenia. However, the biology underlying this statistical evidence is unclear. Statistical polygenic risk for schizophrenia is associated with working memory, while other biological evidence involves miR-137 in emotion processing. We investigated the function of miR-137 target schizophrenia risk genes in humans. We identified a prefrontal co-expression pathway of schizophrenia-associated miR-137 targets and validated the association with miR-137 expression in neuroblastoma cells. Alleles predicting greater co-expression of this pathway were associated with greater prefrontal activation during emotion processing in two independent cohorts of healthy volunteers (N1=222; N2=136). Statistical polygenic risk for schizophrenia was instead associated with prefrontal activation during working memory. A co-expression pathway links miR-137 and its target genes to emotion processing and risk for schizophrenia. Low prefrontal miR-137 expression may be related with SCZ risk via increased expression of target risk genes, itself associated with increased prefrontal activation during emotion processing.

neuroscience↗

bioRxiv2019

Brain state stability during working memory is explained by network control theory, modulated by dopamine D1/D2 receptor function, and diminished in schizophrenia

Dynamical brain state transitions are critical for flexible working memory but the network mechanisms are incompletely understood. Here, we show that working memory entails brain-wide switching between activity states. The stability of states relates to dopamine D1 receptor gene expression while state transitions are influenced by D2 receptor expression and pharmacological modulation. Schizophrenia patients show altered network control properties, including a more diverse energy landscape and decreased stability of working memory representations.

neuroscience↗

bioRxiv2018

Genetic control of variability in subcortical and intracranial volumes

Sensitivity to external demands is essential for adaptation to dynamic environments, but comes at the cost of increased risk of adverse outcomes when facing poor environmental conditions. Here, we apply a novel methodology to perform genome-wide association analysis of mean and variance in nine key brain features (accumbens, amygdala, caudate, hippocampus, pallidum, putamen, thalamus, intracranial volume and cortical thickness), integrating genetic and neuroanatomical data from a large lifespan sample (n=25,575 individuals; 8 to 89 years, mean age 51.9 years). We identify genetic loci associated with phenotypic variability in cortical thickness, thalamus, pallidum, and intracranial volumes. The variance-controlling loci included genes with a documented role in brain and mental health and were not associated with the mean anatomical volumes. This proof-of-principle of the hypothesis of a genetic regulation of brain volume variability contributes to establishing the genetic basis of phenotypic variance (i.e., heritability), allows identifying different degrees of brain robustness across individuals, and opens new research avenues in the search for mechanisms controlling brain and mental health.

neuroscience↗

bioRxiv2018

The dark side of the mean: brain structural heterogeneity in schizophrenia and its polygenic risk.

ImportanceBetween-subject variability in brain structure is determined by gene-environment interactions, possibly reflecting differential sensitivity to environmental and genetic perturbations. Magnetic resonance imaging (MRI) studies have revealed thinner cortices and smaller subcortical volumes in patients. However, such group-level comparisons may mask considerable within-group heterogeneity, which has largely remained unnoticed in the literature\n\nObjectiveTo compare brain structural variability between individuals with SZ and healthy controls (HC) and to test if respective variability reflects the polygenic risk for SZ (PRS) in HC.\n\nDesign, Setting, and ParticipantsWe compared MRI derived cortical thickness and subcortical volumes between 2,010 healthy controls and 1,151 patients with SZ across 16 cohorts. Secondly, we tested for associations between PRS and MRI features in 12,490 participants from UK Biobank.\n\nMain Outcomes and MeasuresWe modeled mean and dispersion effects of SZ and PRS using double generalized linear models. We performed vertex-wise analyses for thickness, and region-of-interest analysis for cortical, subcortical and hippocampal subfield volumes. Follow-up analyses included within-sample analysis, controlling for intracranial volume and population covariates, test of robustness of PRS threshold, and outlier removal.\n\nResultsCompared to controls, patients with SZ showed higher heterogeneity in cortical thickness, cortical and ventricle volumes, and hippocampal subfields. Higher PRS was associated with thinner frontal and temporal cortices, as well as smaller left CA2/3, but was not significantly associated with dispersion.\n\nConclusion and relevanceSZ is associated with substantial brain structural heterogeneity beyond the mean differences. These findings possibly reflect higher differential sensitivity to environmental and genetic perturbations in patients, supporting the heterogeneous nature of SZ. Higher PRS for SZ was associated with thinner fronto-temporal cortices and smaller subcortical volumes, but there were no significant associations with the heterogeneity in these measures, i.e. the variability among individuals with high PRS were comparable to the variability among individuals with low PRS. This suggests that brain variability in SZ results from interactions between environmental and genetic factors that are not captured by the PGR. Factors contributing to heterogeneity in fronto-temporal cortices and hippocampus are thus key to further our understanding of how genetic and environmental factors shape brain biology in SZ.\n\nKey PointsQuestion: Is schizophrenia and its polygenic risk associated with brain structural heterogeneity in addition to mean changes?\n\nFindings: In a sample of 1151 patients and 2010 controls, schizophrenia was associated with increased heterogeneity in fronto-temporal thickness, cortical, ventricle, and hippocampal volumes, besides robust reductions in mean estimates. In an independent sample of 12,490 controls, polygenic risk for schizophrenia was associated with thinner fronto-temporal cortices and smaller CA2/3 of the left hippocampus, but not with heterogeneity.\n\nMeaning: Schizophrenia is associated with increased inter-individual differences in brainstructure, possibly reflecting clinical heterogeneity, gene-environment interactions, or secondary disease factors.

neuroscience↗

bioRxiv2018

Increased Cerebral Blood Flow after single dose of antipsychotics in healthy volunteers depends on dopamine D2 receptor density profiles.

As a result of neuro-vascular coupling, the functional effects of antipsychotics in human brain have been investigated in both healthy and clinical populations using haemodynamic markers such as regional Cerebral Blood Flow (rCBF). However, the relationship between observed haemodynamic effects and the pharmacological action of these drugs has not been fully established. Here, we analysed MRI-based rCBF data from a placebo-controlled study in healthy volunteers, who received a single dose of three different D2 receptor antagonists and tested the association of the main effects of the drugs on rCBF against normative population maps of D2R protein density and gene-expression data. In particular, we correlated CBF changes after antipsychotic administration with non-displaceable binding potential (BPND) template maps of the high affinity D2-antagonist Positron Emission Tomography (PET) ligand [18F]Fallypride and brain post-mortem microarray mRNA expression data for the DRD2 gene. For all antipsychotics, rCBF changes were directly proportional to brain D2R densities and DRD2 mRNA expression measures, although PET BPND spatial profiles explained more variance as compared with mRNA profiles (PET R2 range= 0.20-0.60, mRNA PET R2 range 0.04-0.20, pairwise-comparisons all p<0.05). In addition, the spatial coupling between {Delta}CBF and D2R profiles varied between the different antipsychotics tested, possibly reflecting differential affinities. Overall, these results indicate that the functional effects of antipsychotics as measured with rCBF are tightly correlated with the distribution of their target receptors in striatal and extra-striatal regions. Our results further demonstrate the link between neurotransmitter targets and haemodynamic changes reinforcing rCBF as a robust in-vivo marker of drug effects. This work is important in bridging the gap between pharmacokinetic and pharmacodynamics of novel and existing compounds.

pharmacology and toxicology↗

bioRxiv2018

Prefrontal co-expression of schizophrenia risk genes is associated with treatment response in patients

Gene co-expression networks are relevant to functional and clinical translation of schizophrenia (SCZ) risk genes. We hypothesized that SCZ risk genes may converge into coexpression pathways which may be associated with gene regulation mechanisms and with response to treatment in patients with SCZ. We identified gene co-expression networks in two prefrontal cortex post-mortem RNA sequencing datasets (total N=688) and replicated them in four more datasets (total N=227). We identified and replicated (all p-values<.001) a single module enriched for SCZ risk loci (13 risk genes in 10 loci). In silico screening of potential regulators of the SCZ risk module via bioinformatic analyses identified two transcription factors and three miRNAs associated with the risk module. To translate post-mortem information into clinical phenotypes, we identified polymorphisms predicting co-expression and combined them to obtain an index approximating module co-expression (Polygenic Co-expression Index: PCI). The PCI-co-expression association was successfully replicated in two independent brain transcriptome datasets (total N=131; all p-values<.05). Finally, we tested the association between the PCI and short-term treatment response in two independent samples of patients with SCZ treated with olanzapine (total N=167). The PCI was associated with treatment response in the positive symptom domain in both clinical cohorts (all p-values<.05).\n\nIn summary, our findings in a large sample of human post-mortem prefrontal cortex show that coexpression of a set of genes enriched for schizophrenia risk genes is relevant to treatment response. This co-expression pathway may be co-regulated by transcription factors and miRNA associated with it.

neuroscience↗

bioRxiv2018

Brain scans from 21297 individuals reveal the genetic architecture of hippocampal subfield volumes

The hippocampus is a heterogeneous structure, comprising histologically distinguishable subfields. These subfields are differentially involved in memory consolidation, spatial navigation and pattern separation, complex functions often impaired in individuals with brain disorders characterized by reduced hippocampal volume, including Alzheimers disease (AD) and schizophrenia. Given the structural and functional heterogeneity of the hippocampal formation, we sought to characterize the subfields genetic architecture. T1-weighted brain scans (n=21297, 16 cohorts) were processed with the hippocampal subfields algorithm in FreeSurfer v6.0. We ran a genome-wide association analysis on each subfield, covarying for total hippocampal volume. We further calculated the single nucleotide polymorphism (SNP)-based heritability of twelve subfields, as well as their genetic correlation with each other, with other structural brain features, and with AD and schizophrenia. All outcome measures were corrected for age, sex, and intracranial volume. We found 15 unique genome-wide significant loci across six subfields, of which eight had not been previously linked to the hippocampus. Top SNPs were mapped to genes associated with neuronal differentiation, locomotor behaviour, schizophrenia and AD. The volumes of all the subfields were estimated to be heritable (h2 from .14 to .27, all p< 1x10-16) and clustered together based on their genetic correlations compared to other structural brain features. There was also evidence of genetic overlap of subicular subfield volumes with schizophrenia. We conclude that hippocampal subfields have partly distinct genetic determinants associated with specific biological processes and traits. Taking into account this specificity may increase our understanding of hippocampal neurobiology and associated pathologies.

genetics↗